Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone

Journal of Endocrinology

Volumn 193, Issue 1, 2007, Pages 171-182

  Kato, Norihiko ^a   Kitahara, Keiichiro ^a   Rittling, Susan R ^b   Nakashima, Kazuhisa ^a   Denhardt, David T ^c   Kurosawa, Hisashi ^d   Ezura, Yoichi ^a   Noda, Masaki ^a,e,f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b FORSYTH INSTITUTE   (United States)

^c State University of New Jersey   (United States)

^d JUNTENDO UNIVERSITY   (Japan)

^e Program for Frontier Research on Molecular Destruction and Reconstruction of Tooth and Bone   (Japan)

^f JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONO AE 1 329; OSTEOPONTIN; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MINERAL; BONE MINERALIZATION; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; WILD TYPE;

ALKALINE PHOSPHATASE; AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; COLLAGEN TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; GENE EXPRESSION; INJECTIONS, SUBCUTANEOUS; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOGENESIS; OSTEOPONTIN; OSTEOPOROSIS; OVARIECTOMY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFHYDRYL COMPOUNDS; THIOPHENES; TOMOGRAPHY, X-RAY COMPUTED; TRANSCRIPTION FACTORS;

EID: 34247338970     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06917     Document Type: Article

References (42)

1. Akhter MP, Cullen DM, Gong G & Recker RR 2001 Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 29 121-125.
2. Boskey AL, Spevak L, Paschalis E, Doty SB & McKee MD 2002 Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcified Tissue International 71 145-154.
3. Ducy P, Desbois C, Boyce B, Pinero G, Strory B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C et al. 1996 Increased bone formation in osteocalcin-deficient mice. Nature 382 448-452.
4. Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N et al. 1999 Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. PNAS 96 10501-10506.
5. Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi DT & Miller TA 2004 Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone 34 799-808.
6. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC & Goldberg HA 1996 Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochemical Journal 317 59-64.
7. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A & Noda M 2002 Resistance to unloadoing-induced three-dimensional bone loss in osteopontin-deficient mice. Journal of Bone and Mineral Research 17 661-667.
8. Jono S, Peinado C & Giachelli CM 2000 Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. Journal of Biological Chemistry 275 20197-20203.
9. Jorgensen HRI, Svanholm H & Host A 1998 Bone formation induced in an infant by systemic prostaglandin-E2 administration. Acta Orthopaedica Scandinavica 59 464-466.
10. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Esuboi K, Sugimoto Y, Kobayashi T & Miyachi Y 2002 The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. Journal of Clinical Investigation 105 469-478.
11. Ke HZ, Crawford DT, Qi H, Simmons HA, Owen TA, Paralkar VM, Li M, Lu B, Grasser WA, Cameron KO et al. 2006 A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. Journal of Bone and Mineral Research 21 565-575.
12. Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CR, Breyer RM & Raisz LG 2000 Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141 2054-2061.
13. Li X, Tomita M, Pilbeam CC, Breyer RM & Raisz LG 2002 Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. Prostaglandin and Other Lipid Mediators 67 173-180.
14. Li M, Ke HZ, Qi H, Healy DR, Li Y, Crawford DT, Paralkar VN, Owen TA, Cameron KO, Lefker BA et al. 2003 A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. Journal of Bone and Mineral Research 18 2033-2042.
15. Li M, Healy DR, Li Y, Simmons HA, Crawford DT, Ke HZ, Pan LC, Brown TA & Thompson DD 2005 Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone 37 46-54.
16. Lian JB & Stein GS 1995 Development of the osteoblast phenotype: molecular mechanisms mediating osteoblast growth and differentiation. Iowa Orthopaedic Journal 15 118-140.
17. Makita S, Nakamura M, Ohhira A, Itoh S & Hiramori K 1997 Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans. Cardiovascular Drugs and Therapy 11 441-448.
18. Morinobu M, Nakamoto T, Hino K, Tsuji K, Shen ZJ, Nakashima K, Nifuji A, Yamamoto H, Hirai H & Noda M 2005 The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic protein-induced bone formation. Journal of Experimental Medicine 201 961-970.
19. Narumiya S, Sugimoto U & Ushikubi F 1999 Prostanoid receptors: structure, properties, and functions. Physiological Reviews 79 1193-1226.
20. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ & Haylock DN 2005 Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106 1232-1239.
21. Noda M & Denhardt DT 2002 Osteopontin. In Principles of Bone Biology, 2, pp 239-250. Eds JP Bilezikian, LG Raisz & GA Rodan. San Diego: Academic Press.
22. Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA & Hunter GK 2004 Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochemical Journal 378 1083-1087.
23. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM & Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. Journal of Bone and Mineral Research 2 595-610.
24. Perry PV, Crawford DT, Qi H, Ke H & Pan LC 2000 Systemic prostaglandin E2 administration induces bone loss in mice by a mechanism that requires the EP4 but not the EP2 receptor subtype. Journal of Bone and Mineral Research S224.
25. Pilbeam CC, Harrison JR & Raisz LG 2002 Prostaglandins and bone metabolism. In Principles of Bone Biology, 2nd edn, pp 979-994. Eds JP Bilezikian, LG Raisz & GA Rodan. San Diego: Academic Press.
26. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An X-R, Novick KE, Kowalski AJ, Noda M & Denhardt DT 1998 Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. Journal of Bone and Mineral Research 13 1101-1111.
27. Rodan GA & Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289 1508-1514.
28. Rosen CJ & Bilezikian JP 2001 Clinical review 123: hot topic. Anabolic therapy for osteoporosis. Journal of Clinical Endocrinology and Metabolism 86 957-964.
29. Sasaoka R, Terai H, Toyoda H, Imai Y, Sugama R & Takaoka K 2004 A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2. Biochemical and Biophysical Research Commununications 318 704-709.
30. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, Hirose M et al. 1998 Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochemical and Biophysical Research Communications 246 7-12.
31. Shamir D, Keila S & Weinreb M 2004 A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone 34 157-162.
32. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR et al. 2005 Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. Journal of Experimental Medicine 201 1781-1791.
33. Suponitzky I & Weinreb M 1998 Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. Journal of Endocrinology 156 51-57.
34. Swarthout JT, D'Alonz RC, Selvamurugan N & Partridge NC 2002 Parathyroid hormone-dependent singaling pathways regulating genes in bone cells. Gene 282 1-17.
35. Tanaka M, Sakai A, Uchida S, Tanaka S, Nagashima M, Katayama T, Yamaguchi K & Nakamura T 2004 Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34 940-948.
36. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE & Chung LWK 1999 Osteopontin: possible role in prostate cancer progression. Clinical Cancer Research 5 2271-2277.
37. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A et al. 1998 Impaired ferbrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395 281-284.
38. Usui M, Yoshida Y, Yamashita T, Tsuji K, Ishikawa I, Yamamoto T, Nifuji A & Noda M 2002 Enhancing effect of Tob deficiency on bone formation is specific to bone morphogenetic protein-induced osteogenesis. Journal of Bone and Mineral Research 17 1026-1033.
39. Yang RS, Liu TK & Lin-Shiau SY 1993 Increased bone growth by local prostaglandin E2 in rats. Calcified Tissue International 52 57-61.
40. Yone K, Sakou T & Kawauchi Y 1999 The effect of lipo prostaglandin E1 on cauda equina bood flow in patients with lumbar spinal canal stenosis: myeloscopic observation. Spinal Cord 37 269-274.
41. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, Yamaguchi K, Segi E, Tsuboyama T, Matsushita M et al. 2002 Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. PNAS 99 4580-4585.
42. Yoshitake H, Rittling SR, Denhardt DT & Noda M 1999 Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. PNAS 96 8156-8160.